Alvotech’s AVT05 Biosimilar Application Accepted by EMA
Company Announcements

Alvotech’s AVT05 Biosimilar Application Accepted by EMA

Alvotech (ALVO) has released an update.

Alvotech, in collaboration with Advanz Pharma, has announced the acceptance of its Marketing Authorization Application for AVT05, a proposed biosimilar to Simponi, by the European Medicines Agency. This milestone marks a significant step in expanding treatment options for chronic inflammatory diseases in Europe. The development reflects Alvotech’s commitment to providing high-quality, cost-effective biosimilar medicines to global markets.

For further insights into ALVO stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyAlvotech announces EMA acceptance of MAA for AVT05
TipRanks Auto-Generated NewsdeskAlvotech and Teva Secure FDA Approval for SELARSDI
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App